Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CGEN logo CGEN
Upturn stock ratingUpturn stock rating
CGEN logo

Compugen (CGEN)

Upturn stock ratingUpturn stock rating
$1.4
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CGEN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.25

1 Year Target Price $6.25

Analysts Price Target For last 52 week
$6.25 Target price
52w Low $1.13
Current$1.4
52w High $2.66

Analysis of Past Performance

Type Stock
Historic Profit 210.59%
Avg. Invested days 43
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 137.10M USD
Price to earnings Ratio -
1Y Target Price 6.25
Price to earnings Ratio -
1Y Target Price 6.25
Volume (30-day avg) 4
Beta 2.62
52 Weeks Range 1.13 - 2.66
Updated Date 08/28/2025
52 Weeks Range 1.13 - 2.66
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.22

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate -0.06
Actual -0.08

Profitability

Profit Margin -87.45%
Operating Margin (TTM) -670.57%

Management Effectiveness

Return on Assets (TTM) -11.43%
Return on Equity (TTM) -35.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 45299379
Price to Sales(TTM) 6.19
Enterprise Value 45299379
Price to Sales(TTM) 6.19
Enterprise Value to Revenue 2.05
Enterprise Value to EBITDA -19.16
Shares Outstanding 93535400
Shares Floating 91623494
Shares Outstanding 93535400
Shares Floating 91623494
Percent Insiders 2.03
Percent Institutions 16.52

ai summary icon Upturn AI SWOT

Compugen

stock logo

Company Overview

overview logo History and Background

Compugen Ltd. was founded in 1993 in Israel. It is a computational drug discovery company focused on discovering novel drug targets and developing therapeutics, primarily in immuno-oncology.

business area logo Core Business Areas

  • Drug Discovery: Compugen utilizes its computational discovery platforms to identify novel drug targets, particularly in immuno-oncology.
  • Therapeutic Development: The company develops therapeutic candidates based on its discovered targets, advancing them through preclinical and clinical stages.
  • Licensing and Partnerships: Compugen aims to monetize its discoveries through licensing agreements and partnerships with pharmaceutical companies.

leadership logo Leadership and Structure

The company is led by a management team with experience in biotechnology and drug development. The organizational structure typically includes research, development, clinical, and business development departments.

Top Products and Market Share

overview logo Key Offerings

  • COM701: A first-in-class antibody targeting PVRIG, a novel immune checkpoint, currently in clinical trials for solid tumors. Market share data is not yet available as it is still in clinical development. Competitors include companies developing similar checkpoint inhibitors, such as those targeting PD-1/PD-L1. Potential competitors with overlapping mechanisms are still emerging.
  • BAY 1905254 (formerly COM902): A first-in-class antibody targeting TIGIT, being developed in collaboration with Bayer. Market share data is not available as it is still in clinical development. Competitors include companies like Roche (TIGIT inhibitor tiragolumab), Gilead (domvanalimab), and Arcus Biosciences.

Market Dynamics

industry overview logo Industry Overview

The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, focused on developing therapies that harness the body's immune system to fight cancer.

Positioning

Compugen positions itself as an innovator in computational drug discovery, specializing in identifying novel immune checkpoint targets. Its competitive advantage lies in its proprietary computational platforms and first-in-class assets.

Total Addressable Market (TAM)

The total addressable market for immuno-oncology is expected to reach hundreds of billions of dollars in the coming years. Compugen is positioned to capture a share of this market through the successful development and commercialization of its pipeline assets.

Upturn SWOT Analysis

Strengths

  • Proprietary computational drug discovery platforms
  • Novel immune checkpoint targets (PVRIG, TIGIT)
  • Strategic partnerships with major pharmaceutical companies (Bayer)
  • First-in-class therapeutic candidates
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on clinical trial success
  • High R&D costs
  • Competition from larger pharmaceutical companies
  • Limited revenue stream
  • Dependency on partners for commercialization

Opportunities

  • Expansion of pipeline with new drug targets
  • Successful clinical trial outcomes for COM701 and BAY 1905254
  • Further collaborations and licensing agreements
  • Advancements in computational biology and AI
  • Personalized medicine and biomarker discovery

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other immuno-oncology therapies
  • Patent challenges
  • Changes in the healthcare landscape

Competitors and Market Share

competitor logo Key Competitors

  • Roche (RHHBY)
  • Gilead (GILD)
  • Arcus Biosciences (RCUS)
  • Bristol Myers Squibb (BMY)

Competitive Landscape

Compugen's advantage lies in its novel targets, but it faces strong competition from larger companies with more resources and established products.

Major Acquisitions

Not Applicable

  • Year: 2024
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: NA

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the advancement of its pipeline and the securing of partnerships with pharmaceutical companies.

Future Projections: Future growth is contingent on successful clinical trial outcomes for COM701 and BAY 1905254, as well as the development of new drug targets. Analyst estimates would be the best source for revenue projections.

Recent Initiatives: Recent strategic initiatives include ongoing clinical trials for COM701, continued collaboration with Bayer on BAY 1905254, and the advancement of new preclinical programs.

Summary

Compugen is a computational drug discovery company with promising novel targets and strategic partnerships that could lead to future growth. However, it faces risks associated with clinical trials and competition from larger pharmaceutical firms. Success hinges on the development of its pipeline, and it is still considered a risky stock due to its developmental stage. The company's computational drug discovery approach offers a unique advantage, but it needs to validate this approach with successful commercial products.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Compugen's investor relations website
  • SEC filings
  • Company press releases
  • Analyst reports (various sources)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source and methodology. Financial data is based on publicly available information. Always conduct thorough research and consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Compugen

Exchange NASDAQ
Headquaters -
IPO Launch date 2000-08-11
CEO, President & Director Dr. Anat Cohen-Dayag Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 74
Full time employees 74

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.